Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Docetaxel
100%
Phase II Trials
33%
Infection
16%
Supportive Care
16%
Survival Rate
16%
Antineoplastic Activity
16%
Neutropenia
16%
Dexamethasone
16%
Median Survival Time
16%
Febrile Neutropenia
16%
Fluid Retention
16%
Diseases
16%
Chemotherapy
16%
Immunology and Microbiology
Survival Rate
100%
Dexamethasone
100%
Antineoplastic Activity
100%
Median Survival Time
100%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Docetaxel
100%
Phase II Trials
33%
Survival Rate
16%
Infection
16%
Chemotherapy
16%
Neutropenia
16%
Antitumor Activity
16%
Dexamethasone
16%
Median Survival Time
16%
Febrile Neutropenia
16%
Diseases
16%
Keyphrases
Platinum-refractory
50%
Response Status
33%
Platinum Sensitivity
16%
Platinum-refractory Disease
16%
Refractory Patients
16%
Platinum Response
16%